Order byBest matchMost fresh

FDA, Peter Marks

Digest more
Top News
Event details
Impacts
Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency’s leadership ranks and threatens to unmoor the oversight of drugs and vaccines from bed...
From STAT
Peter Marks, who played a key role in President Donald Trump's first term in developing COVID-19 vaccines, will leave effective April 5, the Wall Street Journal and other media outlets reported on Fr...
From Reuters
Vaccine makers’ stocks fell as the market opened Monday, with most companies’ stocks staying down at close.
From Politico

Read more on News Digest

Follow the Science: Why Peter Marks Was Asked to Leave the FDA
Dr. Peter Marks announced his resignation from the U.S. Food and Drug Administration (FDA) as Director of CEBR (Center for Biologics Evaluation and Research) citing differences with Health and Human Services (HHS) Secretary Kennedy regarding vaccines.
FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences
Peter Marks’ ouster comes at a time when the sector is already suffering through a years-long public markets slump.
Top vaccine official Peter Marks forced out at FDA, WSJ reports
The U.S. Food and Drug Administration's top vaccine official, Peter Marks, has been pushed out, the Wall Street Journal reported on Friday. Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines,
Drugmakers sink after key FDA official ousted as Trump plans health overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official, Peter Marks, had been forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Moderna (NASDAQ:MRNA) Leads U.S. Biotechs’ Plunge after FDA’s Top Vaccine Regulator Resigns
Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine official at the U.S.
Biotech Investors Rush for the Exits After FDA Official Resigns
Biotech investors are reeling after the sudden departure of Peter Marks, a pivotal figure in the U.S. Food and Drug Administration. Marks, who played a crucial role in Operation Warp Speed and champio
The Peter Marks effect
The pharma industry, Wall Street and former government officials on Monday decried the forced resignation of FDA vaccine regulator Dr. Peter Marks, openly worrying that his exit portends an antiscience shift at the agency.
Biotech Stocks Tumble on Reports FDA's Top Vaccine Regulator to Leave
Greg Nash/Pool via REUTERS (Reuters) -Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned,
Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research
STAT16h
Marks’ exit is not exactly helping industry sentiment
Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary Robert F. Kennedy Jr. on vaccines. Moderna’s stock dropped 9%, while Vaxcyte’s plummeted 46% (though shares of Vaxcyte were also affected by disappointing results of a vaccine candidate.)
Fierce Pharma1d
As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Who Is Dr. Peter Marks? FDA’s Top Vaccine Official Quits, Citing RFK Jr.’s ‘Misinformation And Lies.’
Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific truth” impacting public health.
Fierce Pharma17h
FDA's new commissioner Marty Makary signed off on Peter Marks ouster: Politico
It's not yet been a week since Marty Makary, M.D., was confirmed to lead the FDA as its commissioner. | Peter Marks, M.D., Ph.D., a target for RFK Jr. and allies, last week turned in his resignation as director of the FDA's Center for Biologics Evaluation and Research.
Explore more
BioSpace15h
Biotech’s ‘Worst Fear’ Comes True as FDA’s Marks Departs, Sending Shares Tumbling
Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma markets.
STAT1d
Emotional whiplash for PTC Therapeutics
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in treatment, nearly tripling the number of patients eligible for its use. Phase 3 data showed a 59% reduction in the risk of disease progression or death, cementing Pluvicto’s status as the crown jewel of radioligand therapy.
Feedback